Strategies for the prevention of hip fracture.
暂无分享,去创建一个
[1] G E Dallal,et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.
[2] S. Cummings,et al. Bone density at various sites for prediction of hip fractures , 1993, The Lancet.
[3] O. Johnell,et al. Risk of Hip Fracture Derived from Relative Risks: An Analysis Applied to the Population of Sweden , 2000, Osteoporosis International.
[4] S. Cummings,et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.
[5] J. Cauley,et al. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. , 1997, Archives of Internal Medicine.
[6] M. Morris,et al. Clinical Reporting to Primary Care Physicians Leads to Increased Use and Understanding of Bone Densitometry and Affects the Management of Osteoporosis , 1998, Annals of Internal Medicine.
[7] T. Harris,et al. Prevalence of low femoral bone density in older U.S. women from NHANES III , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] S. Cummings,et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.
[9] B. Dawson-Hughes,et al. Calcium Supplement and Bone Medication Use in a US Medicare Health Maintenance Organization , 2002, Osteoporosis International.
[10] O. Geling,et al. Missed opportunities for prevention of osteoporotic fracture. , 2002, Archives of internal medicine.
[11] D. Kiel,et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.
[12] Orthopaedic Surgeons Panel On Falls Prevention. Guideline for the Prevention of Falls in Older Persons , 2001 .
[13] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[14] M. Hochberg,et al. Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1996 .
[15] A. Berg. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions , 2003 .
[16] David W. Bates,et al. CLINICAL USE OF BONE DENSITOMETRY , 1991 .
[17] J. Kaufman,et al. Interest of a Prescreening Questionnaire to Reduce the Cost of Bone Densitometry , 2002, Osteoporosis International.
[18] P. Dargent-Molina,et al. Use of Clinical Risk Factors in Elderly Women with Low Bone Mineral Density to Identify Women at Higher Risk of Hip Fracture: The EPIDOS Prospective Study , 2002, Osteoporosis International.
[19] Mahmood Puzirandeh. Does patient partnership in continuing medical education (CME) improve the outcome in osteoporosis management? , 2002 .
[20] François Duboeuf,et al. Vitamin D3 and Calcium to Prevent Hip Fractures in Elderly Women , 1993 .
[21] B. Ettinger,et al. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. , 2002, Menopause.
[22] L. Gillespie,et al. Hip protectors for preventing hip fractures in the elderly. , 2001, The Cochrane database of systematic reviews.
[23] G. Guyatt,et al. IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis , 2002 .
[24] E. Barrett-Connor,et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. , 2001, JAMA.
[25] Harry K. Genant,et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .
[26] K. Fink,et al. Screening for osteoporosis in postmenopausal women. , 2004, American family physician.
[27] E. Barrett-Connor,et al. Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial , 2002 .
[28] J. Peipert,et al. Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale , 2002, Annals of Internal Medicine.
[29] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[30] Deborah Grady,et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.
[31] R. Parker,et al. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. , 2003, JAMA.
[32] Lex M Bouter,et al. Prevention of hip fractures by external hip protectors: a randomized controlled trial. , 2003, JAMA.
[33] V. Kaklamani,et al. Assessment of physician responses to abnormal results of bone densitometry studies. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[34] Lillemor Lundin-Olsson,et al. Fall and Injury Prevention in Older People Living in Residential Care Facilities: A Cluster Randomized Trial , 2002, Annals of Internal Medicine.
[35] B. Kvern,et al. Evaluation of a problem‐based learning workshop using pre‐ and post‐test objective structured clinical examinations and standardized patients , 2000, The Journal of continuing education in the health professions.
[36] O. Johnell,et al. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .
[37] S. Cummings,et al. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .
[38] Gordon Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.
[39] A. Warnke,et al. controlled trial protectors in nursing homes: cluster randomised Effect on hip fractures of increased use of hip , 2004 .
[40] E. Barrett-Connor,et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. , 2002, JAMA.
[41] G. Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. , 2002, Endocrine reviews.
[42] E. Vittinghoff,et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.
[43] S. Cummings,et al. Clinical use of bone densitometry: scientific review. , 2002, JAMA.
[44] J. Reginster,et al. Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis , 2002 .
[45] B. Ettinger,et al. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. , 1998, The American journal of managed care.
[46] Gabriele Meyer,et al. Effect on hip fractures of increased use of hip protectors in nursing homes: cluster randomised controlled trial , 2003, BMJ : British Medical Journal.
[47] Stephen B. Hulley,et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II) , 2002 .
[48] L. Bouter,et al. Ultrasound Measurements for the Prediction of Osteoporotic Fractures in Elderly People , 1999, Osteoporosis International.
[49] Susan Mehle,et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. , 2002, Mayo Clinic proceedings.
[50] I. Zuckerman,et al. Patterns of pharmacotherapy and counseling for osteoporosis management in visits to US ambulatory care physicians by women. , 2002, Archives of internal medicine.
[51] B. Stuckey,et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. , 2003, Archives of internal medicine.
[52] Y. Carter,et al. Education and debate , 2022 .
[53] P. Geusens,et al. Performance of risk indices for identifying low bone density in postmenopausal women. , 2002, Mayo Clinic proceedings.
[54] M S Calvo,et al. Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[55] Stella M. Yu. Healthy People 2010 , 1998, Maternal and Child Health Journal.
[56] L. Melton,et al. Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[57] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[58] Susan R. Johnson,et al. Osteoporosis prevention, diagnosis, and therapy. , 2001, JAMA.
[59] J. Vahle,et al. Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety , 2002, Toxicologic pathology.
[60] Michael C. Nevitt,et al. Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial , 2001 .
[61] S. Cummings,et al. Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.
[62] Uspstf. Postmenopausal hormone replacement therapy for the primary prevention of chronic condition. Recommendations and rationale. U.S. Preventive Services Task Force. , 2003, American family physician.
[63] Dami,et al. EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN , 2001 .
[64] M. Hochberg,et al. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis , 2001 .
[65] R. Doll,et al. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.